E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027599 |
E.1.2 | Term | Migraine |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Compare the pharmacokinetics of Dihydroergotamine Mesylate delivered by oral inhalation (MAP0004) or intravenously (IV) (DHE 45) in smokers versus non-smokers |
|
E.2.2 | Secondary objectives of the trial |
• Identify whether there are clinically significant differences in the tolerability of MAP0004 between smokers and non-smokers |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Able to provide written informed consent 2. Male or Female subjects 18 to 45 years old 3. Female subjects who are practicing adequate contraception or who are sterile 4. Stable cardiac status 5. Normal rhythm or arrhythmia deemed clinically insignificant on ECG 6. Heart rate ≥ 40 and ≤ 100 at Visit 1 vital signs assessment (resting) 7. QTcF (Fridericia’s Correction) ≤ 450 msec 8. Non smokers: never smoked or total exposure <1 pack year and at least 12 months since last cigarette with a negative urinary cotinine result at screening 9. Smokers: currently smoking at least 10 cigarettes/day for at least 1 year with a positive urinary cotinine result at screening 10. Demonstrated ability to properly use the Tempo® Inhaler |
|
E.4 | Principal exclusion criteria |
1. Contraindication to dihydroergotamine mesylate (DHE) 2. Use of any excluded concomitant medications within the 10 days prior to Visit 1 3. History of hemiplegic or basilar migraine 4. Participation in another investigational trial during the 30 days prior to Visit 1 or during this trial 5. Diagnosis of cancer (other than a non-invasive skin cancer) within the 5 years prior to Visit 1 6. Major surgery, vascular surgery or sepsis during the 6 months prior to Visit 1 (major surgery is defined as any surgery requiring general anesthesia and hospitalization for ≥ 2 days post operatively) 7. History of unstable psychiatric illness requiring medication or hospitalization in the 12 months leading up to Visit 1 8. Subjects who have known allergy or sensitivity to study drugs or their formulations 9. Women who are pregnant, breast feeding or plan a pregnancy during this trial 10. Clinically significant liver (any/all of SGPT > 150U/L; SGOT > 130 U/L or LDH > 750 U/L) or kidney disease (serum creatinine > 4.0 mg/dL) 11. History of chronic pulmonary disease 12. History of coronary artery disease (CAD), coronary vasospasm (including Prinzmetal’s angina), aortic aneurysm, peripheral vascular disease or other ischemic diseases (e.g., ischemic bowel syndrome or Raynaud’s syndrome) 13. The following CAD risk factor: • Hypertension (systolic BP > 140 or diastolic BP > 90) Or any 2 of the following 4 CAD risk factors: • Receiving anti hypertensive medication for the treatment of hypertension. • Hyperlipidemia – (LDL) > 159 mg/dL and/or (HDL) < 40 mg/dL (or on prescribed anti cholesterol treatment) • Family history of premature coronary artery disease (CAD) (< 55 years of age in male first degree relatives or < 65 years of age in female first degree relatives) • Diabetes mellitus 14. History of cerebral vascular accident (CVA), transient ischemic attacks (TIA), or seizures 15. History of concurrent illness that requires hospitalization within the 30 days prior to Visit 1 16. History of bronchospasm with any inhaled medication or other inhaled substance, such as CFC or HFA propellants 17. Subjects who have received other diagnostic or research radiation exposure in the last 12 months, with the exception of routine dental x-rays 18. Any condition that, in the opinion of the Investigator, would make the subject unsuitable for study participation and completion, including but not limited to: • Any reason to believe that compliance with the study requirements and completion of evaluations required for this study will not be possible • Any language barrier that, in the opinion of the Investigator, would preclude communication and compliance with the study requirements • History or current abuse or dependence on alcohol or drugs that would interfere with adherence to study requirements • Any clinically relevant abnormal findings in the physical exam, vital signs or laboratory tests that, in the opinion of the Investigator, may put the subject at risk |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The Primary Endpoints to be measured in this study are DHE and metabolite of DHE, namely 8’ OH DHE levels as follows: • Cmax: maximal plasma concentration • Tmax: time at which maximal plasma concentration is observed • AUC 0-48: area under the plasma concentration versus time curve, as determined by a trapezoidal method, from time zero to 48 hours post-dose. • AUC 0-inf: area under the plasma concentration versus time curve, from time zero to time infinity. • T1/2: elimination half-life of DHE parent drug from the plasma
The Secondary Endpoints to be measured in this study are as follows: • Clinical AEs • Laboratory evaluations • Vital signs • ECG • FEV1
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is the last subject's last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |